The theory that raised blood homocysteine is a major factor in the development of cardiovascular disease was initially rejected by the medical establishment. Trials of a treatment to lower homocysteine in moderately advanced disease have failed to show benefits (except in those not treated with anti-platelet drug), but there is mounting evidence for a role in treatment of very early disease and as a preventive strategy. Recent evidence has shown that lowering of high blood homocysteine significantly slows cognitive decline and the brain shrinkage associated with Alzheimer’s disease. This is a test that should be done more frequently by National Health Service (NHS) general practitioners and private practitioners.
BonaaKHNjolstadIUelandPM. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. New England Journal of Medicine354(15): 1578–1588.
2.
ClarkeRBennettDParishS. (2014) Effects of homocysteine lowering with B vitamins on cognitive aging: Meta-analysis of 11 trials with cognitive data on 22,000 individuals. American Journal of Clinical Nutrition100(2): 657–666.
3.
ClarkeRSmithADJobstKA. (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Archives of Neurology55(11): 1449–1455.
4.
DawsonSLBoweSJCroweTC (2016) A combination of omega-3 fatty acids, folic acid and B-group vitamins is superior at lowering homocysteine than omega-3 alone: A meta-analysis. Nutrition Research36(6): 499–508. Epub ahead of print. DOI: 10.1016/j.nutres.2016.03.010.
5.
DouaudGRefsumHde JagerCA. (2013) Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proceedings of the National Academy of Sciences of the United States of America110(23): 9523–9528.
6.
DurgaJVan BoxtelMPJSchoutenEG. (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet369(9557): 208–216.
7.
HankeyGJEikelboomJWYiQ. (2012) Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: A posthoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurology11(6): 512–520.
8.
HuoYLiJQinX. (2015) Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: The CSPPT randomized clinical trial. Journal of the American Medical Association313(13): 1325–1335.
9.
LonnEYusufSArnoldMJ. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine354(15): 1567–1577.
10.
McCaddonAMillerJW (2015) Assessing the association between homocysteine and cognition: Reflections on Bradford Hill, meta-analyses and causality. Nutrition Reviews73(10): 723–735.
11.
McCullyKS (1996) Homocysteine and vascular disease. Nature Medicine2(4): 386–389.
12.
McCullyKSRagsdaleBD (1970) Production of arteriosclerosis by homocysteinemia. American Journal of Pathology61(1): 1–11.
13.
NygardONordrehaugJERefsumH. (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. New England Journal of Medicine337(4): 230–236.
14.
OulhajAJernerénFRefsumH. (2016) Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in Mild Cognitive Impairment. Journal of Alzheimer’s Disease50(2): 547–557.
15.
ParkJHSaposnikGOvbiageleB. (2016) Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. International Journal of Stroke11(2): 206–211.
16.
RefsumHSmithADUelandPM. (2004) Facts and recommendations about total homocysteine determinations: An expert opinion. Clinical Chemistry50(1): 3–32.
17.
SmithADRefsumH (2016) Homocysteine, B vitamins, and cognitive impairment. Annual Review of Nutrition36: 211–239.
18.
SmithADSmithSMde JagerCA. (2010) Homocysteine-lowering by b vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. Public Library of Science One5(9): e12244.
19.
TsiachristasASmithAD (2016) B-vitamins are potentially a cost-effective population health strategy to tackle dementia: Too good to be true?Alzheimer’s Dementia (NY)2(3): 156–161.
20.
WaldDSLawMMorrisJK (2002) Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. British Medical Journal325(7374): 1202–1209.
21.
WaldDSWaldNJMorrisJK. (2006) Folic acid, homocysteine and cardiovascular disease: Judging causality in the face of inconclusive trial evidence. British Medical Journal333(7578): 1114–1117.
22.
WangXQinXDemirtasH. (2007) Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet369(9576): 1876–1882.
23.
YangQBottoLDEricksonJD. (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation113(10): 1335–1343.
